FAP-activated therapeutic agents, and uses related thereto
Disclosed are prodrugs of anthracyclines (such as doxorubicin) and derivatives thereof that are selectively cleaved and activated by fibroblast activating protein (FAP). The prodrugs are useful for targeted delivery of “warhead” anthracycline or anthracycline derivative to FAP-expressing tissues, including cancer (e.g., solid tumors). Also provided are pharmaceutical compounds comprising the prodrugs, as well as methods of using the prodrugs to treat a disorder characterized by FAP upregulation, e.g., cancer, undesirable fibrosis, and undesirable inflammation.
1. A pharmaceutical preparation for intravenous administration, comprising a buffering solution having dissolved therein a prodrug represented by Formula I, or a lyophilized preparation of the prodrug for forming an intravenous solution:
or a pharmaceutically acceptable salt thereof, wherein:
R 1 represents (C 1 -C 10 )alkyl, (C 1 -C 10 )alkoxy, (C 1 -C 10 )alkyl-C(O)(C 1 -C 10 )alkyl, (C 3 -C 8 )cycloalkyl, (C 3 -C 8 )cycloalkyl(C 1 -C 10 )alkyl, aryl, aryl(C 1 -C 10 )alkyl, heteroaryl, or heteroaryl(C 1 -C 10 )alkyl, wherein any R 1 is optionally substituted with one or more substituents independently selected from the group consisting of halo, hydroxy, carboxylate, cyano, amino, nitro, and —SH;
or
represents an N-terminally blocked alpha amino acid residue, wherein X is O;
R 2 represents H or a (C 1 -C 6 )alkyl;
R 3 represents a (C 1 -C 6 )alkyl;
R 4 is absent or represents a (C 1 -C 6 )alkyl, —OH, —NH 2 , or halogen;
X represents O or S;
L represents a bond,
or
represents a self-immolative linker; and
Cyt′ represents a radical of an anthracycline or derivative thereof.
2. The pharmaceutical preparation of claim 1 , wherein L is a bond.
3. The pharmaceutical preparation of claim 1 , wherein the anthracycline or derivative thereof is doxorubicin.
4. The pharmaceutical preparation of claim 1 , wherein L is a self-immolative linker.
5. The pharmaceutical preparation of claim 4 , wherein the anthracycline or derivative thereof is doxorubicin.
6. The pharmaceutical preparation of claim 1 , wherein R 2 is H.
7. The pharmaceutical preparation of claim 1 , wherein R 3 is methyl, ethyl, propyl, or isopropyl.
8. The pharmaceutical preparation of claim 1 , wherein R 3 is methyl.
9. The pharmaceutical preparation of claim 1 , wherein
represents an N-terminally blocked alpha amino acid residue, wherein X is O, which comprises a moiety which, at physiological pH, reduces cell permeability of the prodrug relative to the anthracycline or derivative thereof.
10. The pharmaceutical preparation of claim 1 , wherein
represents an N-terminally blocked alpha amino acid residue, wherein X is O, which comprises one or more functional groups that are ionized at physiological pH.
11. The pharmaceutical preparation of claim 1 , wherein
represents an N-terminally blocked alpha amino acid residue, wherein X is O, and the terminal blocking group is an acyl(C 1 -C 10 )alkyl substituted with one or more functional groups that are ionized at physiological pH.
12. The pharmaceutical preparation of claim 11 , wherein
represents an N-terminally blocked alpha amino acid residue, wherein X is O, and the terminal blocking group is represented by the formula HO 2 C—(C 1 -C 10 )alkyl-C(O)—.
13. The pharmaceutical preparation of claim 11 , wherein
represents an N-terminally blocked alpha amino acid residue, wherein X is O, and the terminal blocking group is represented by the formula HO 2 C—(CH 2 ) 2 —C(O)—.
14. The pharmaceutical preparation of claim 1 , wherein
represents an N-terminally blocked alpha amino acid residue, wherein X is O, and the terminal blocking group is selected from the group consisting of formyl, dansyl, acetyl, benzoyl, trifluoroacetyl, succinyl, and methoxysuccinyl.
15. The pharmaceutical preparation of claim 1 , wherein
represents an N-terminally blocked alpha amino acid residue, wherein X is O, and the terminal blocking group is selected from the group consisting of aryl(C 1 -C 6 )acyl and heteroaryl(C 1 -C 6 )acyl.
16. The pharmaceutical preparation of claim 15 , wherein
represents an N-terminally blocked alpha amino acid residue, wherein X is O, and the terminal blocking group is an aryl(C 1 -C 6 )acyl.
17. The pharmaceutical preparation of claim 16 , wherein the aryl(C 1 -C 6 )acyl is a (C 1 -C 6 )acyl substituted with an aryl selected from the group consisting of benzyl, naphthalenyl, phenanthrenyl, phenolyl, and anilinyl.
18. The pharmaceutical preparation of claim 17 , wherein the aryl(C 1 -C 6 )acyl is a (C 1 )acyl substituted with an aryl selected from the group consisting of benzyl, naphthalenyl, phenanthrenyl, phenolyl, and anilinyl.
19. The pharmaceutical preparation of claim 15 , wherein
represents an N-terminally blocked alpha amino acid residue, wherein X is O, and the terminal blocking group is a heteroaryl(C 1 -C 6 )acyl.
20. The pharmaceutical preparation of claim 19 , wherein the heteroaryl(C 1 -C 6 )acyl is a (C 1 -C 6 )acyl substituted with a heteroaryl selected from the group consisting of pyrryl, furyl, thiophenyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, pyrazolyl, pyridinyl, pyrazinyl, pyridazinyl, and pyrimidinyl.
21. The pharmaceutical preparation of claim 20 , wherein the heteroaryl(C 1 -C 6 )acyl is a (C 1 -C 6 )acyl substituted with a heteroaryl selected from the group consisting of pyrryl, furyl, thiophenyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, pyrazolyl, pyridinyl, pyrazinyl, pyridazinyl, and pyrimidinyl.
22. The pharmaceutical preparation of claim 1 , wherein X is O, and
is acyl(C 1 -C 10 )alkyl substituted with one or more functional groups that are ionized at physiological pH.
23. The pharmaceutical preparation of claim 1 , wherein X is O, and
is HO 2 C—(C 1 -C 10 )alkyl-C(O)—.
24. The pharmaceutical preparation of claim 1 , wherein X is O, and
is HO 2 C—(CH 2 ) 2 —C(O)—.
25. The pharmaceutical preparation of claim 1 , wherein X is O, and
is selected from the group consisting of formyl, dansyl, acetyl, benzoyl, trifluoroacetyl, succinyl, and methoxysuccinyl.
26. The pharmaceutical preparation of claim 1 , wherein X is O, and
is selected from the group consisting of aryl(C 1 -C 6 )acyl and heteroaryl(C 1 -C 6 )acyl.
27. The pharmaceutical preparation of claim 26 , wherein X is O, and
is aryl(C 1 -C 6 )acyl.
28. The pharmaceutical preparation of claim 27 , wherein aryl(C 1 -C 6 )acyl is a (C 1 -C 6 )acyl substituted with an aryl selected from the group consisting of benzyl, naphthalenyl, phenanthrenyl, phenolyl, and anilinyl.
29. The pharmaceutical preparation of claim 28 , wherein aryl(C 1 -C 6 )acyl is a (C 1 )acyl substituted with an aryl selected from the group consisting of benzyl, naphthalenyl, phenanthrenyl, phenolyl, and anilinyl.
30. The pharmaceutical preparation of claim 26 , wherein X is O, and
is heteroaryl(C 1 -C 6 )acyl.
31. The pharmaceutical preparation of claim 30 , wherein heteroaryl(C 1 -C 6 )acyl is a (C 1 -C 6 )acyl substituted with a heteroaryl selected from the group consisting of pyrryl, furyl, thiophenyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, pyrazolyl, pyridinyl, pyrazinyl, pyridazinyl, and pyrimidinyl.
32. The pharmaceutical preparation of claim 31 , wherein heteroaryl(C 1 -C 6 )acyl is a (C 1 )acyl substituted with a heteroaryl selected from the group consisting of pyrryl, furyl, thiophenyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, pyrazolyl, pyridinyl, pyrazinyl, pyridazinyl, and pyrimidinyl.
33. A pharmaceutical preparation for intravenous administration, comprising a buffering solution having dissolved therein a prodrug represented by the Formula
or a lyophilized preparation of the prodrug for forming an intravenous solution.